Every 8-K that Biofrontera Inc. Warrants (BFRIW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BFRIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BFRIW filings page.
Biofrontera Inc. (BFRI) reports that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for Ameluz topical gel, 10%, used with the BF‑RhodoLED lamp series for treatment of superficial basal cell carcinoma (sBCC) in adults. Ameluz is now the first and only photodynamic therapy approved in the United States to treat a skin cancer and the only topical PDT indicated for both actinic keratosis and a skin cancer.
The company states that this new sBCC indication broadens Ameluz’s addressable market and supports its strategy to expand its red‑light PDT platform. In a Phase 3 trial of 187 adults with sBCC, complete clinical and histological response of the main target lesion at 12 weeks was achieved in 66% of Ameluz PDT patients versus 5% with placebo PDT. Biofrontera plans an official launch of the sBCC indication in late fourth quarter 2026 through first quarter 2027 using its existing commercial organization and installed lamp base.
Biofrontera Inc. reported a strong improvement in operating performance for the quarter and six months ended June 30, 2026. Second-quarter net product revenue was $12.0 million, up 32.9% from $9.0 million, with gross margin rising to 80% from 71% as a new Ameluz® cost structure took hold. Quarterly net loss narrowed sharply to $0.6 million ($(0.05) per share) from $5.3 million ($(0.57) per share), and Adjusted EBITDA improved to $(0.2) million from $(5.1) million.
For the first half of 2026, net product revenue grew 25.4% to $22.1 million, with gross margin at 80% versus 67%. Net loss decreased to $5.4 million ($(0.44) per share) from $9.5 million, while Adjusted EBITDA improved to $(3.7) million from $(9.5) million. Cash used in operating activities fell to $1.7 million from $7.2 million, including a $3.7 million related-party paydown. Cash and equivalents were $4.7 million and stockholders’ equity was $6.0 million as of June 30, 2026. The company noted an International Trade Commission exclusion order affecting its RhodoLED XL lamp from July 7, 2026 but does not expect it to change full-year 2026 revenue goals.
Biofrontera Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected Beth J. Hoffman, Ph.D. and Kevin D. Weber as Class II directors, with each receiving over 8.0 million votes in favor and more than 3.3 million broker non-votes recorded.
Investors also approved an amendment and restatement of the 2021 Omnibus Incentive Plan, increasing the total number of common shares authorized under the plan from 3,750,000 to 8,750,000, with about 7.9 million votes cast in favor. In addition, stockholders ratified CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with approximately 10.9 million votes for the proposal.
Biofrontera Inc. reported solid Q1 2026 progress, with revenue of $10.1 million, up about 17% from $8.6 million a year earlier, driven by higher Ameluz unit volumes and a price increase. Gross margin improved sharply to roughly 80% from 62%, reflecting a new earnout structure after its 2025 strategic transaction.
Operating loss narrowed slightly to $4.3 million, while net loss was $4.8 million, or $0.41 per share, compared with $4.2 million, or $0.47 per share. Adjusted EBITDA improved to a loss of $3.6 million, and operating cash usage was only $70 thousand, leaving $6.3 million in cash as of March 31, 2026.
The company highlighted key pipeline and regulatory milestones, including FDA filing acceptance of an sNDA for Ameluz PDT in superficial basal cell carcinoma with a PDUFA target action date of September 28, 2026, positive Phase 3 data in actinic keratoses on additional body sites, positive Phase 2b acne results, and regaining compliance with the Nasdaq Minimum Bid Price Requirement.
Biofrontera Inc. reported positive Phase 2b clinical results for its Ameluz® photodynamic therapy in moderate to severe acne vulgaris. In the 3-hour incubation per-protocol group, Ameluz achieved a 57.97% reduction in inflammatory lesions versus 36.51% with vehicle, and 25% of Ameluz patients met the mIGA co-primary endpoint compared with 21.4% on vehicle.
The 3-hour regimen also showed larger absolute reductions in inflammatory, non-inflammatory and total lesion counts and a safety profile consistent with prior PDT experience, with mainly mild to moderate burning and itching. Patient satisfaction was high, and the company plans to present these Phase 2b data to the FDA in Q3 2026 to discuss potential next development steps.
Biofrontera Inc. reports a significant development in its patent dispute with Sun Pharmaceutical Industries. On February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun’s U.S. Patent No. 11,697,028 unpatentable.
Sun may still request rehearing, seek review by the Director of the U.S. Patent and Trademark Office, or appeal to the U.S. Court of Appeals for the Federal Circuit, so the outcome is not yet final. The company notes that the impact of this decision on ongoing proceedings in the U.S. District Court for the District of Massachusetts and the International Trade Commission cannot be determined at this time.
Biofrontera Inc. reported positive, statistically significant Phase 3 results for Ameluz® photodynamic therapy (PDT) to treat mild to moderate actinic keratoses on the extremities, neck, and trunk using its RhodoLED® platform.
Ameluz® PDT achieved complete clearance in 45.6% of patients in the Full Analysis Set, versus 16.7% with vehicle PDT (p < 0.0003), and 53.2% versus 22.2% in the Per Protocol Set (p < 0.001). Lesion clearance reached 73.1% in the Full Analysis Set and 80.3% in the Per Protocol Set. Investigators rated cosmetic outcomes as good or very good in 75.2% of patients, and 86.3% indicated they would choose PDT again. Based on these data, Biofrontera plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026 for a potential label expansion beyond the face and scalp.
Biofrontera, Inc. reported results from a special shareholder meeting where shareholders holding 8,403,861 votes were present for proposals one, three, and four, and shareholders holding 6,820,211 votes were present for proposal two, constituting a quorum for all proposals. The filing states that the meeting was solicited under Regulation 14A and that there was no solicitation in opposition. The proxy statement filed on August 5, 2025 is cited as the source for the detailed descriptions of the proposals. The document indicates that the meeting "summarizes all matters voted on," but it does not include the vote tallies or explicit outcomes for each proposal within the provided text.
Biofrontera Inc. furnished a press release announcing its financial and operational results for the three and six months ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the Company states it includes non-GAAP financial measures with quantitative reconciliations to the most directly comparable GAAP measures in accordance with Regulation G. The filing explicitly notes this information is being furnished rather than filed and therefore is not subject to Section 18 liability nor automatically incorporated by reference in registration statements. The Form 8-K also identifies the registrant as an emerging growth company and lists its registered securities, including common stock (BFRI) and warrants (BFRIW) traded on Nasdaq. This Form 8-K does not include numeric financial results; readers must refer to the attached press release for the detailed figures.
Biofrontera Inc. announced the appointment of George Jones as Chief Commercial Officer, with his role to commence on August 25, 2025. Mr. Jones brings more than 25 years of commercial leadership in pharmaceuticals and biotech, most recently serving as Chief Operating Officer at UpScriptHealth and previously holding senior commercial roles at Currax Pharmaceuticals.
The company entered into an Employment Agreement providing an annual base salary of $315,000, a bonus opportunity up to 50% of base salary, and at least 100,000 stock options that vest in three tranches after each of the first three full years of service and are subject to the company’s option program terms. The agreement includes severance provisions that specify prorated monthly payments by year of service with a stated minimum of six months and reference to two full years, enhanced change-in-control benefits, and customary confidentiality, non-competition, non-solicitation, indemnification, and expense reimbursement terms.